JosephJEronJr.MD

Infectious Disease • Chapel Hill, NC

Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine

Join to view full profile

Dr. Eron is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Eron's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 919-966-4996

Fax+1 919-843-5515

Education & Training

Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1989 - 1992
Massachusetts General HospitalResidency, Internal Medicine, 1984 - 1987
Harvard Medical SchoolClass of 1984

Certifications & Licensure

NC State Medical License 1992 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients
Completed
Phase 1
Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV
Completed
Phase 2
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults Start of enrollment: 2003 Oct 01
Completed
Not Applicable
Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults Start of enrollment: 2009 Apr 01
Completed
Phase 2
The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART Start of enrollment: 2011 Feb 01
Completed
Phase 1, Phase 2
Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera Start of enrollment: 2012 Oct 01
Completed
Join now to see all

Publications & Presentations

PubMed

Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial.
Kara W Chew, Babafemi O Taiwo, Carlee Moser, Eric S Daar, David Alain Wohl
The Journal of Infectious Diseases. 2024-11-15
1 citations
SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback.
Nathaniel Bloom, Sydney I Ramirez, Hallie Cohn, Urvi M Parikh, Amy Heaps
The Journal of Infectious Diseases. 2024-11-15
Rapid viral suppression using integrase inhibitors during acute HIV-1 infection.
Mehri S McKellar, Jessica R Keys, Lindsey M Filiatreau, Kara S McGee, Joann D Kuruc
The Journal of Antimicrobial Chemotherapy. 2024-11-06

Journal Articles

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Michael S Saag, Melanie A Thompson, Constance A Benson, Susan P Buchbinder, Joseph J Eron, Donna M Jacobsen, JAMA
Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-Uninfected Individuals: HPTN 077, a Phase 2a Randomized Controlled Trial
Susan H Eshleman, Joseph J Eron, Raphael J Landovitz, Myron S Cohen, Jeremy Sugarman, Mark A Marzinke, Craig W Hendrix, PLoS One
HIV Viral Suppression Trends over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study
Kenneth H Mayer, W Christopher Mathews, Michael J Mugavero, Katerina A Christopoulos, Richard D Moore, Benigno Rodriguez, Joseph J Eron, Michael S Saag, Mari M Kitahat..., Annals of Internal Medicine
Using Primer-ID Deep Sequencing to Detect Recent HIV-1 Infection
Ann M Dennis, Joseph J Eron, Myron S Cohen, Christopher J Sellers, The Journal of Infectious Diseases
Join now to see all

Lectures

2013 Interscience Conference On Antimicrobial Agents & Chemotherapy
American Society For Microbology, Denver, Colorado - 9/10/2013

Press Mentions

Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIVFebruary 22nd, 2023
Mass General Brigham Sites Begin Phase 3 Trial Evaluating Monkeypox TreatmentOctober 19th, 2022
UCLA to Participate in Phase 3 Trial Evaluating Monkeypox TreatmentSeptember 13th, 2022
Join now to see all

Grant Support

University Of North Carolina AIDS Clinical Trials Unit (Unc Actu)National Institute Of Allergy And Infectious Diseases2007–2012
Persistent CSF HIV Despite Successful CART: Viral Tropism, Drug Penetration AndNational Institute Of Mental Health2011
Clinical CoreNational Institute Of Allergy And Infectious Diseases2006–2011
Clinical Trial: Adult AIDS Clinical Trials Group Longitudinal Linked RandomizedNational Center For Research Resources2008
Chavi 001: Acute HIV-1 Infection Prospective Cohort StudyNational Center For Research Resources2007–2008
In Vitro Assessment Of Immunogenicity Of AT2 Inactivated Autologous VirionsNational Center For Research Resources2006–2008
Aactg 5175 - Drug Combinations For Initial Treatment Of HIV-1 Infected SubjectsNational Center For Research Resources2006–2008
Measure The Clearance Or Replication-Competent HIV-1 In Resting Memory Cd4+CellsNational Center For Research Resources2005–2008
PLAN For Obtaining Informed Consent To Use Stored Human Biological MaterialsNational Center For Research Resources2004–2008
Antiretroviral Therapy For Hiv-Infected Adults With Acute Infections:National Center For Research Resources2004–2008
Lamivudine PLUS Stavudine PLUS Abacavir PLUS Amprenavir/RitonaverNational Center For Research Resources2007
Regimen Simplification To Atazanavir/Ritonavir Alone As MaintenanceNational Center For Research Resources2006–2007
Longitudinal Assessment Of Acute HIV InfectionNational Center For Research Resources2005–2007
Adult AIDS Clinical Trials Group Longitudinal Linked Randomized TrialsNational Center For Research Resources2004–2007
Predictors Of Immunologic And Clinical Progression In Subjects With CD4+ CellNational Center For Research Resources2004–2006
Phenotypic Susceptibility (C12h/Ic50) On Antiretroviral Response To RitonavirNational Center For Research Resources2004–2006
Immunization Strategy With ALVAC-HIV Vcp1452 In HIV-1 SubjectsNational Center For Research Resources2004–2006
Adult Therapeutic Clinical Trials Program For AIDSNational Institute Of Allergy And Infectious Diseases2002–2006
Two Regimens Utilizing A Protease Inhibitor-Sparing Regimen VS NucleosideNational Center For Research Resources2005
Lopinavir/Ritonavir VS Gw433908 And Ritonavir VS Lopinavir/Ritonavir And Gw433National Center For Research Resources2004–2005
Two Regimens Utilizing A Protease Inhibitor-Sparing Regimen Vs. NucleosideNational Center For Research Resources2004
Treatment Of HIV With Stavudine, Didanosine, And NevirapineNational Center For Research Resources2004
ACTG 372: Virologic Success/Options For Virologic Failure In HIVNational Center For Research Resources2004
Phase I/II Study Of A Vrp VaccineNational Institute Of Allergy And Infectious Diseases2002
Treatment Of HIV W/ Stavudine, Didanosine, &NevirapineNational Center For Research Resources1999–2002
T 20 Administered To HIV 1 Adults By Continuous Subcutaneous InfusionNational Center For Research Resources1999–2002
Plasma Pharmacokinetics, &Antiviral Activity Of T 20 In HIVNational Center For Research Resources1999–2002
Long Term Safety Profile Of 141W94 In HIV SubjectsNational Center For Research Resources1999–2002
Intrasubject Variability Of Excretion Of HIV In Vaginal SecretionsNational Center For Research Resources1999–2002
HIV 1 Infected Subjects Response To Combinations Of DDI &HydroxyureaNational Center For Research Resources1999–2002
Four Drug Regimen VS Three Drug Regimen In HIV Infected SubjectsNational Center For Research Resources1999–2002
Delavirdine Mesylate In Triple &Quadruple Combinations In HIV 1National Center For Research Resources1999–2002
Combination Therapy W/ 1592u89, 141w94, &Dmp 266 In HIVNational Center For Research Resources1999–2002
Abt378 &Ritonavir In Protease Inhibitor Experienced HIV PatientsNational Center For Research Resources1999–2002
Zidovudine, Lamivudine And Indinavir In HIV PatientsNational Center For Research Resources1998–2002
Zerit PLUS Videx Versus Retrovir PLUS Epivir In HIV Seropositive SubjectsNational Center For Research Resources1998–2002
ZDV Resistant HIV Virus In Women And Evaluation Of Long Term EffectivenessNational Center For Research Resources1998–2002
Virologic Success/Options For Virologic Failure In HIVNational Center For Research Resources1998–2002
Virologic And Immunologic Activity Of Continued LamivudineNational Center For Research Resources1998–2002
Study Of Indinavir Sulfate (IDV) And 1592689 In HIV InfectionNational Center For Research Resources1998–2002
Study Of 141w94/Vx-478 Monotherapy Versus 141w9/VxNational Center For Research Resources1998–2002
Soft Gelatin Capsule Of Sqvsgc In Combination With Ritonavir Or NelfinNational Center For Research Resources1998–2002
Phase I/II Screening Trial To Identify Potential Partner CompoundsNational Center For Research Resources1998–2002
Intrasubject Variability Of Excretion Of HIV In Semen Over TimeNational Center For Research Resources1998–2002
Epivir, Retrovir And Protease Inhibitor Versus 3TC With Protease InhibitorNational Center For Research Resources1998–2002
Comparison Of Virologic Efficacy Of Nelfinavir AND/OR Dmp-266National Center For Research Resources1998–2002
Abt378/Ritonavir In Combination With Reverse Transcriptase Inhibitors In HIVNational Center For Research Resources1998–2002
141w94/Vx-478 PLUS 3TC PLUS ZDV Or Indinavir PLUS Nevirapine PLUS 3TC In HIVNational Center For Research Resources1998–2002
Three Fixed Doses Of Delavirdine With ZDV VS ZDV Alone In HIV InfectionNational Center For Research Resources1997–2002
Study Of Viracept In Combination With ZDV + 3TC VS AZT + 3TC In HIV PatientsNational Center For Research Resources1997–2002
L-735,524 And Zidovudine VS L-735,524 VS Zidovudine In HIV InfectionNational Center For Research Resources1997–2002
Hydroxyurea Alone &In Combination W/ DDI VS DDI In Patients With HIV InfectionNational Center For Research Resources1997–2002
Mk639 Administered In Combination With Zidovudine &3tc VS ZDV &3tc VS Mk639National Center For Research Resources1996–2002
Zerit PLUS Videx Versus Retrovir PLUS Epivir In HIV PTSNational Center For Research Resources2000
Viracept In Combination W/ ZDV + 3TC VS AZT + 3TC In HIV PTSNational Center For Research Resources2000
STC VS Dlv/Idv/Zdv Or D4T In HIV InfectionNational Center For Research Resources2000
Saquinavir/Ritonavir Or Nelfinavir/Delavirdine/Or Adefovir Dipivoxilin In HIV PTSNational Center For Research Resources2000
Recombinant Human Interleukin-12 In HIV Infected PTSNational Center For Research Resources2000
Protocol For HIV Infected Adults W/ Prior T-20 TreatmentNational Center For Research Resources2000
Pharmacokinetics Of Oral DAPD In HIV-1 Infected PTSNational Center For Research Resources2000
Mk639 In Combination W/ Zidovudine &3tc VS ZDV &3tc VS Mk639National Center For Research Resources2000
L-735,524 &Zidovudine VS L-735,524 VS Zidovudine In HIV InfectionNational Center For Research Resources2000
Indinavir Sulfate W/ Ritonavir In HIV Infected PatientsNational Center For Research Resources2000
Indinavir Sulfate (Idv), Dmp-266 &1592689 In HIV InfectionNational Center For Research Resources2000
Hydroxyurea In HIV PTS On Potent Antiretroviral TherapyNational Center For Research Resources2000
Hydroxyurea &In Combination W/ DDI VS DDI In HIV InfectionNational Center For Research Resources2000
Effects Ofamprenavir, Abacavir &3tc In HIV Infected PTSNational Center For Research Resources2000
Dynamics Of Hepatitis C Infection In PTS W/ HCV &HivNational Center For Research Resources2000
Ddl/D4t/Hu VS Ddl/D4t/Efv VS Protease Inhibitor In HIV PTSNational Center For Research Resources2000
Azithromycin Prophylaxis For Primary Prevention Of MACNational Center For Research Resources2000
Antiviral Activity Of T-1249 In HIV-1 Infected AdultsNational Center For Research Resources2000
Abt378/Ritonavir W/ Reverse Transcriptase Inhibitors In HIVNational Center For Research Resources2000
141w94/Vx-478/ 3tc/ ZDV Or Indinavir/ Nevirapine/ 3TC In HIVNational Center For Research Resources2000
Core--Behavioral/ClinicalEunice Kennedy Shriver National Institute Of Child Health &Human Development1998–2000
Virologic Response To New Nucleoside Regimens After Prolonged ZDV Or DDI In HIVNational Center For Research Resources1997–1999
Virologic And Immunologic Effects Of ZDV VS D4T VS ZDV In HIV Infected PatientsNational Center For Research Resources1997–1999
Study Of Viracept As Monotherapy In HIV Positive PatientsNational Center For Research Resources1997–1999
Phase III Ritonavir Long Term Treatment Trial In HIV (Abbott M96-432)National Center For Research Resources1997–1999
Influence Of Risk Status For Disease Progression To Antiretroviral In HIVNational Center For Research Resources1997–1999
Differences Among Various Zdv/Ddi Regimens On Viral Burden In HIV InfectionNational Center For Research Resources1997–1999
Delavirdine Mesylate Treatment In Triple Combination For HIV-1+ PatientsNational Center For Research Resources1997–1999
ACTG 320--Idu With OPEN Label ZDV And 3TC In Subjects With HIV InfectionNational Center For Research Resources1997–1999
ACTG 306--3tc-Tm In Combination With Zdv, D4T Or DDI VS Monotherapy In HIVNational Center For Research Resources1997–1999
ACTG 193, Version 1.0--Nucleoside Therapy For HIV TreatmentNational Center For Research Resources1997–1999
ACTG 244--Zidovudine VS ZDV And DDI VS ZDV And DDI NevirapineNational Center For Research Resources1996–1999
MN Rgp120/Hiv-1 Vaccine Compared W/Placebo In HIV-1 Seropositive SubjectsNational Center For Research Resources1997
Delavirdine Mesylate With Didanosine VS DDI Alone In HIV InfectionNational Center For Research Resources1997
3TC Monotherapy VS AZT Or ZDV Monotherapy VS 3TC In HIV-1 InfectionNational Center For Research Resources1997
Chronic Nevirapine Dosing In HIV-1 Infected PatientsNational Center For Research Resources1996–1997
Virologic Response To New Nucleoside Regimens After Prolonged ZDVNational Center For Research Resources1996
Phase II Double Blind Exploratory Study To Evaluate Zdv/Ddi--Actg 276National Center For Research Resources1996
Influence Of Risk Status For Disease Progression On Response To New RegimensNational Center For Research Resources1996
Delvirdine Mesylate Treatment In Triple Combination For HIV+ PatientsNational Center For Research Resources1996
Anti-Hiv Activity Of Delavirdine Mesylate--Actg 260National Center For Research Resources1996
Three Fixed Doses Of Delavirdine With ZDV VS ZDV Alone In HIVNational Center For Research Resources1995–1996
Study Of Delavirdine Mesylate With Didanosine VS DDI AloneNational Center For Research Resources1995–1996
Monotherapy VS Combination Therapy W/ Nucleosides Analogues In HIV Infected PTSNational Center For Research Resources1995–1996
MN Rgp120/Hiv 1 Vaccine Compared With Placebo In HIV 1 Seropositive SubjectsNational Center For Research Resources1995–1996
L-735,524 And Zidovudine VS L-735,524 VS ZidovudineNational Center For Research Resources1995–1996
Assessment Of Two Orally Administered Dosing Regimens ABT 538 In HIVNational Center For Research Resources1995–1996
ACTG 241--Zdv, DDI, And Double Blinded NVP VS ZDV And DDINational Center For Research Resources1995–1996
ACTG 193--Nucleoside Therapy For HIV TreatmentNational Center For Research Resources1995–1996
3TC Monotherapy VS AZT Or ZDV Monotherapy VS 3TC Administered ConcurrentlyNational Center For Research Resources1995–1996
Study Of Hpmpc For The Treatment Of Peripheral Cytomegalovirus In AIDS PatientsNational Center For Research Resources1995
ACTG 244--Zidovudine VS ZDV And DDI ZDV And DDI NevirapineNational Center For Research Resources1995
Quantitation Of Isolation Of Drug Resistant HIV In VitroNational Institute Of Allergy And Infectious Diseases1991